A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that have not been previously treated with Janus kinase inhibitors (JAKi). Pelabresib is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.
Inclusion Criteria:
Exclusion Criteria:
Chandler, Arizona 85224, United States
Decatur, Illinois 62526, United States
Indianapolis, Indiana 46237, United States
New York, New York 10065, United States
Seattle, Washington 98104, United States
Buderim, QLD 4556, Australia
Halle, Saxony 06120, Germany
Nyíregyháza, Hungary
Ampang, Selangor 68000, Malaysia
Ankara, Turkey (Türkiye)
Cambridge, CB2 0QQ, United Kingdom